Kadmon, the drug company founded by Sam Waksal of ImClone and Martha Stewart fame, is starting to look more and more like its founder's last company.» Read More
Aug 21- An experimental new psoriasis treatment from Eli Lilly and Co proved superior to Amgen Inc's blockbuster Enbrel, drawing it closer to a potential marketing battle with new products being developed by Amgen and Novartis AG.
Aug 21- Eli Lilly and Co said its experimental psoriasis drug was found to be more effective in clearing skin than a generic treatment and a placebo in late-stage studies. The most common inflammatory disease in the United States- it can occur on any part of the body- it is associated with diabetes and heart disease.
Aug 21- Eli Lilly and Co said its experimental psoriasis drug was found to be more effective in clearing skin than a generic treatment and a placebo in late-stage studies. Three studies evaluated the drug, ixekizumab, against the generic etanercept and a placebo, in patients with moderate-to-severe plaque psoriasis.
Some of the names on the move ahead of the open.
SAN FRANCISCO, Aug 14- A group of ex-gaming industry executives say they can use their design chops to solve a major health challenge: Sick patients neglecting to take their medication and costing employers and insurance providers billions of dollars.
Aug 14- An Indianapolis church has alleged that JPMorgan Chase& Co mismanaged trust accounts held for its benefit by investing in high cost, risky investments that advanced the firms' interests over its own, according to a lawsuit filed in Indianapolis federal court late on Wednesday.
The companies increasing spending on upgrading equipment and facilities are actually investors’ favorites, USA Today reports.
Aug 11- Biodel Inc said its experimental insulin formulation was found more effective than current therapies in controlling glucose after two meals, in a mid-stage trial. Type 2 diabetes patients are usually given both basal and prandial insulin in a single injection such as Humalog Mix 75/ 25, Biodel said.
Aug 11- Biodel Inc said its experimental insulin formulation was found more effective than current therapies in controlling glucose after two meals, in a mid-stage trial. The company's shares rose about 10 percent to $2.10 before the bell.
*Sanofi, MannKind aim to launch Afrezza in U.S. in Q1 2015. PARIS/ LONDON, Aug 11- French drugmaker Sanofi is betting on inhaled insulin as an alternative option to daily injections for diabetics by signing a worldwide licensing agreement with MannKind Corp worth up to $925 million.
*Novo expects to launch in first EU markets in H1 2015. *Shares in Novo rise 1.6 percent. Prospects for degludec- already on sale separately in Europe under the brand name Tresiba- and the new combination with Victoza are critical for Novo, which is the world's biggest insulin maker.
*Caterpillar weighs on Dow, Facebook hits record on results. NEW YORK, July 24- U.S. stocks barely budged on Thursday as corporate earnings painted a mixed picture of the economy, though the S&P 500 eked out a record intraday high for the third straight session.
*U.S. stocks edge up along with MSCI world index. "The lower-than-expected U.S. initial jobless claims has made people focus on the improving labor market situation," said Ian Lyngen, senior government bond strategist, at CRT Capital in Stamford, Connecticut.
NEW YORK, July 24- Major global stock markets edged higher while the euro rose from an eight-month low against the U.S. dollar on Thursday following upbeat euro zone data and stronger-than-expected U.S. earnings.
NEW YORK, July 24- The S&P 500 hit a record high for a third straight session on Thursday, lifted by jobs data and earnings, but a weak reading in new home sales kept other key stock indexes little changed.
Obama's support of anti-inversion legislation only aims to put a patch on a larger problem—the need for corporate tax reform, CEOs tell CNBC.
July 24- Eli Lilly and Co's quarterly revenue plunged due to generic competition for its Cymbalta depression drug and its Evista osteoporosis treatment, but cost controls helped earnings beat forecasts.
*Facebook rallies on results; market value near IBM's. *U.S. manufacturing data due; Europe, China upbeat. NEW YORK, July 24- U.S. stock index futures rose on Thursday, following a record close on the S&P 500 index, lifted by strong job market data in the United States and overseas factory readings, while better than forecast results sent Facebook shares rallying.
U.S. stock index futures rose on Thursday, ahead of one of the heaviest days for U.S. and European second-quarter earnings.
*U.S. manufacturing data due; Europe, China upbeat. NEW YORK, July 24- U.S. stock index futures rose on Thursday, following a record close on the S&P 500 index, lifted by strong data overseas and better than forecast results from Facebook.